| Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years |
|
Blood Advances |
Aplastic Anemia |
| Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
|
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Guideline-based indicators for adult patients with myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy |
|
Blood Advances |
Aplastic Anemia |
| Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia |
|
Blood Advances |
Aplastic Anemia |
| Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
